Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Factors in Selecting Therapy at First Relapse in Multiple Myeloma

July 18th 2023

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Dr Matous on Ongoing Multiple Myeloma Clinical Trials at Colorado Blood Cancer Institute

July 17th 2023

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the Colorado Blood Cancer Institute.

Dr Matous on the Benefit Derived from the IKEMA Trial in R/R Multiple Myeloma

July 14th 2023

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

Dr Matous on Barriers to CAR T-Cell Therapy Administration in Multiple Myeloma

July 13th 2023

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.

Multiple Myeloma Treatment Advances Promote a Future of Individualized Patient Care

July 11th 2023

Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.

Novel Agents Highlight Changes in Myeloma Field

July 11th 2023

Leading investigators in the multiple myeloma field discuss the latest clinical trial findings, many of which were presented during the 2023 ASCO Annual Meeting.

Patient Scenario: Treatment Options in MM at First Relapse

July 11th 2023

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.

Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

July 11th 2023

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.

Equecabtagene Autoleucel Approved in China for Relapsed/Refractory Multiple Myeloma

July 7th 2023

China’s National Medical Products Administration has approved the new drug application for equecabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma who previously received 3 or more lines of therapy, including a proteasome inhibitor and an immunomodulatory drug.

FDA Awards Orphan Drug Designation to Inobrodib for Multiple Myeloma

July 7th 2023

The FDA has granted orphan drug designation to inobrodib for use as a potential therapeutic option in patients with multiple myeloma.

Earlier Use of Ide-Cel May Increase Benefit for Patients With High-Risk R/R Myeloma

July 6th 2023

Krina K. Patel, MD, MSc, expands on the importance of evaluating outcomes for treatment with ide-cel in patients with relapsed/refractory multiple myeloma with different high-risk characteristics and key findings from the high-risk subgroup analysis of the KarMMa-3 trial.

FDA Approves Ready-to-Dilute Cyclophosphamide Injection for Various Cancers

July 5th 2023

The FDA has approved a new drug application for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy in the treatment of patients with various types of cancers, including malignant lymphoma, multiple myeloma, and various types of leukemia.

Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

July 4th 2023

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

July 4th 2023

Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.

Dr Sasine on the Potential Use of Cilta-Cel in Earlier Lines for Multiple Myeloma

June 30th 2023

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

Dr Oveisi on the Potential Role of Bispecific Antibodies in Multiple Myeloma

June 30th 2023

David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.

Dr Schinke on Talquetamab in Multiple Myeloma

June 30th 2023

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

June 27th 2023

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

Induction Therapy Regimens for Transplant-Eligible NDMM

June 27th 2023

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

June 26th 2023

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.